Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.4K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.4K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab as a sustainable high-efficacy solution for multiple Sclerosis in Brazil.

Arquivos de neuro-psiquiatria·2026
Same author

Global overview of multiple sclerosis care units: an international cross-sectional survey.

Frontiers in neurology·2026
Same author

Building sustainable multiple sclerosis registries in Latin America: A practical framework for real-world evidence generation and healthcare access.

Multiple sclerosis and related disorders·2026
Same author

Collaborative Latin American Imaging Network In Neuroimmunology Research (BRAIMS): Rationale, Structure, Challenges, and Future Directions.

Multiple sclerosis and related disorders·2026
Same author

Double-seronegative neuromyelitis optica: it is not possible to interrupt treatment after 10 years of stability.

Arquivos de neuro-psiquiatria·2026
Same author

Therapeutic plasma exchange for MOG antibody-associated disease attacks: a systematic review and meta-analysis.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: Feb 18, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.0K

MOG-IgG associated optic neuritis is not multiple sclerosis.

Bruna Klein da Costa1,2, Giordani Rodrigues Dos Passos1,2, Jefferson Becker1,2

  • 1Pontifícia Universidade Católica do Rio Grande do Sul, Faculdade de Medicina, Hospital São Lucas, Serviço de Neurologia, Porto Alegre RS, Brasil.

Arquivos De Neuro-Psiquiatria
|November 23, 2017
PubMed
Summary

Myelin oligodendrocyte glycoprotein antibody (MOG-IgG) associated optic neuritis (ON) represents a distinct inflammatory central nervous system (CNS) disease. MOG-IgG positive patients differ from multiple sclerosis (MS) patients in age, sex, and clinical presentation.

More Related Videos

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

84.1K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.6K

Related Experiment Videos

Last Updated: Feb 18, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.0K
Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

84.1K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.6K

Area of Science:

  • Neuroimmunology
  • Demyelinating diseases
  • Central nervous system disorders

Background:

  • Autoantibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) are implicated in inflammatory central nervous system (CNS) disorders.
  • Isolated optic neuritis (ON) is one such disorder where MOG-IgG has been observed.

Purpose of the Study:

  • To compare MOG-IgG positive ON patients with multiple sclerosis (MS) patients presenting with ON.
  • To identify distinct clinical and radiological characteristics differentiating MOG-IgG ON from MS.

Main Methods:

  • Retrospective analysis of patients with optic neuropathies.
  • Comparison of MOG-IgG positive isolated ON patients with MS patients.
  • Cell-based assay for MOG-IgG detection.
  • Analysis of patient demographics, clinical presentation (bilateral/recurrent ON), and brain MRI findings.

Main Results:

  • Six of 38 optic neuropathy patients were MOG-IgG positive isolated ON.
  • Eight patients met diagnostic criteria for MS and were MOG-IgG negative.
  • MOG-IgG positive patients were older (mean 47 years), more frequently male (2:1 ratio), and had more bilateral/recurrent ON.
  • MOG-IgG positive patients showed normal or non-specific white matter lesions on brain MRI.

Conclusions:

  • MOG-IgG is a biomarker for an inflammatory demyelinating CNS disease separate from MS.
  • MOG-IgG associated ON exhibits distinct clinical features compared to MS-associated ON.